טוען...

A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01)(1)

AIMS: The pharmacokinetic (PK) similarity between PF-05280014, a proposed trastuzumab biosimilar, trastuzumab sourced from European Union (trastuzumab-EU) or from United States (trastuzumab-US) was evaluated. Safety and immunogenicity were also assessed. METHODS: In this phase 1, double-blind trial...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Br J Clin Pharmacol
Main Authors: Yin, Donghua, Barker, Kerry B, Li, Ruifeng, Meng, Xu, Reich, Steven D, Ricart, Alejandro D, Rudin, Dan, Taylor, Carrie T, Zacharchuk, Charles M, Hansson, Arne G
פורמט: Artigo
שפה:Inglês
יצא לאור: BlackWell Publishing Ltd 2014
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4256618/
https://ncbi.nlm.nih.gov/pubmed/25041377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12464
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!